MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Ramiro Guerrero bought 11,899 shares of the firm's stock in a transaction on Thursday, August 20th. The stock was purchased at an average price of $1.37 per share, for a total transaction of $16,301.63. Following the completion of the acquisition, the director directly owned 600,117 shares in the company, valued at $822,160.29. The trade was a 2.02% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
MAIA Biotechnology Price Performance
MAIA Biotechnology stock opened at $1.35 on Tuesday. The firm has a 50 day simple moving average of $1.37 and a 200-day simple moving average of $1.46. The stock has a market cap of $82.12 million, a price-to-earnings ratio of -2.18 and a beta of 0.24. MAIA Biotechnology, Inc. has a 1-year low of $0.87 and a 1-year high of $3.19.
MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Equities analysts expect that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of MAIA. Solas Capital Management LLC purchased a new stake in shares of MAIA Biotechnology in the 2nd quarter valued at $4,364,000. Centric Wealth Management purchased a new position in MAIA Biotechnology during the 2nd quarter valued at about $1,107,000. Cable Car Capital LP acquired a new position in MAIA Biotechnology in the 2nd quarter valued at about $741,000. BlackRock Inc. acquired a new position in MAIA Biotechnology in the 2nd quarter valued at about $580,000. Finally, Geode Capital Management LLC increased its stake in MAIA Biotechnology by 9.5% during the fourth quarter. Geode Capital Management LLC now owns 296,740 shares of the company's stock worth $454,000 after purchasing an additional 25,684 shares during the period. Hedge funds and other institutional investors own 5.65% of the company's stock.
About MAIA Biotechnology
(
Get Free Report)
MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.
The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
